RIO DE JANEIRO, BRAZIL – After the University of Oxford announced on Saturday that it will resume trials of its Covid-19 vaccine, Fiocruz reasserted its partnership with AstraZeneca, owner of the production, distribution, and marketing rights of the vaccine being developed by the British university. According to the foundation’s press office, nothing has changed since last Tuesday, when it signed a contract with the laboratory.
Fiocruz is one of the institutions involved in the vaccine research. On September 8th, it signed a technological order contract with AstraZeneca, which ensures access to 100.4 million doses of the active pharmaceutical ingredient for the vaccine’s final processing, and also full technology transfer.
On the same day, the contract was signed, the laboratory and the University of Oxford announced the suspension of phase 3 trials after one of the trial subjects in the UK presented a reaction to the vaccine.
However, on Saturday, the resumption of trials was announced, after reviewing the research.
In a note, the university stated that approximately 18,000 people were administered the vaccine in the study as part of the trial. “In large trials like this, it is expected that some will fall ill and each case needs to be thoroughly analyzed,” reads the note.
Source: Estadão Conteúdo